LABS Fundamental Analysis - MEDIPHARM LABS CORP

Fundamental Rating

Taking everything into account, LABS scores 2 out of 10 in our fundamental rating. LABS was compared to 30 industry peers in the Pharmaceuticals industry. The financial health of LABS is average, but there are quite some concerns on its profitability. LABS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

LABS had negative earnings in the past year.

In the past year LABS has reported a negative cash flow from operations.

In the past 5 years LABS always reported negative net income.

In the past 5 years LABS always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -17.22%, LABS is not doing good in the industry: 63.33% of the companies in the same industry are doing better.

With a Return On Equity value of -21.20%, LABS perfoms like the industry average, outperforming 46.67% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-17.22%
ROE	-21.2%
ROIC	N/A

ROA(3y)-28.72%

ROA(5y)-40.33%

ROE(3y)-34.34%

ROE(5y)-50.73%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LABS's Gross Margin of 25.87% is on the low side compared to the rest of the industry. LABS is outperformed by 66.67% of its industry peers.

LABS's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for LABS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	25.87%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-3.36%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LABS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, LABS has more shares outstanding

The number of shares outstanding for LABS has been increased compared to 5 years ago.

LABS has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.97, we must say that LABS is in the distress zone and has some risk of bankruptcy.

LABS has a Altman-Z score of -1.97. This is in the lower half of the industry: LABS underperforms 70.00% of its industry peers.

LABS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of LABS (0.01) is better than 80.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-1.97

ROIC/WACCN/A

WACC8.84%

2.3 Liquidity

A Current Ratio of 3.20 indicates that LABS has no problem at all paying its short term obligations.

With a decent Current ratio value of 3.20, LABS is doing good in the industry, outperforming 80.00% of the companies in the same industry.

LABS has a Quick Ratio of 2.27. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.

LABS has a better Quick ratio (2.27) than 83.33% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.2
Quick Ratio	2.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.50%, which is quite impressive.

The Revenue has grown by 18.06% in the past year. This is quite good.

The Revenue for LABS have been decreasing by -20.15% on average. This is quite bad

EPS 1Y (TTM)22.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)18.06%

Revenue growth 3Y24.58%

Revenue growth 5Y-20.15%

Sales Q2Q%24.7%

3.2 Future

Based on estimates for the next years, LABS will show a very strong growth in Earnings Per Share. The EPS will grow by 36.84% on average per year.

The Revenue is expected to grow by 14.57% on average over the next years. This is quite good.

EPS Next Y54.1%

EPS Next 2Y36.84%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year13.37%

Revenue Next 2Y14.57%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LABS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LABS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as LABS's earnings are expected to grow with 36.84% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.84%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LABS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDIPHARM LABS CORP

TSX:LABS (12/24/2025, 7:00:00 PM)

0.075

+0 (+7.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-13 2025-11-13/bmo

Earnings (Next)03-30 2026-03-30

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners7.71%

Ins Owner ChangeN/A

Market Cap31.56M

Revenue(TTM)46.10M

Net Income(TTM)-8.03M

Analysts42.22

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-308.5%

Min EPS beat(2)-390.2%

Max EPS beat(2)-226.8%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)6.69%

Min Revenue beat(2)1.03%

Max Revenue beat(2)12.35%

Revenue beat(4)4

Avg Revenue beat(4)5.55%

Min Revenue beat(4)0.49%

Max Revenue beat(4)12.35%

Revenue beat(8)6

Avg Revenue beat(8)0.54%

Revenue beat(12)6

Avg Revenue beat(12)-4.9%

Revenue beat(16)7

Avg Revenue beat(16)-3.8%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)-20%

EPS NY rev (3m)-20%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-6.21%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.68
P/FCF	N/A
P/OCF	N/A
P/B	0.83
P/tB	0.85
EV/EBITDA	N/A

EPS(TTM)-0.03

EYN/A

EPS(NY)-0.01

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0.11

BVpS0.09

TBVpS0.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.22%
ROE	-21.2%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	25.87%
FCFM	N/A

ROA(3y)-28.72%

ROA(5y)-40.33%

ROE(3y)-34.34%

ROE(5y)-50.73%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-3.36%

F-Score5

Asset Turnover0.99

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	7.89%
Cap/Sales	0.31%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.2
Quick Ratio	2.27
Altman-Z	-1.97

F-Score5

WACC8.84%

ROIC/WACCN/A

Cap/Depr(3y)18.2%

Cap/Depr(5y)27.57%

Cap/Sales(3y)1.89%

Cap/Sales(5y)6.02%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)22.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y54.1%

EPS Next 2Y36.84%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)18.06%

Revenue growth 3Y24.58%

Revenue growth 5Y-20.15%

Sales Q2Q%24.7%

Revenue Next Year13.37%

Revenue Next 2Y14.57%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y34.13%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year84.07%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y51.16%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y49.89%

OCF growth 3YN/A

OCF growth 5YN/A

MEDIPHARM LABS CORP / LABS.CA FAQ

What is the ChartMill fundamental rating of MEDIPHARM LABS CORP (LABS.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LABS.CA.

Can you provide the valuation status for MEDIPHARM LABS CORP?

ChartMill assigns a valuation rating of 1 / 10 to MEDIPHARM LABS CORP (LABS.CA). This can be considered as Overvalued.

How profitable is MEDIPHARM LABS CORP (LABS.CA) stock?

MEDIPHARM LABS CORP (LABS.CA) has a profitability rating of 0 / 10.

Can you provide the financial health for LABS stock?

The financial health rating of MEDIPHARM LABS CORP (LABS.CA) is 5 / 10.

MEDIPHARM LABS CORP (LABS.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDIPHARM LABS CORP / LABS.CA FAQ

What is the ChartMill fundamental rating of MEDIPHARM LABS CORP (LABS.CA) stock?

Can you provide the valuation status for MEDIPHARM LABS CORP?

How profitable is MEDIPHARM LABS CORP (LABS.CA) stock?

Can you provide the financial health for LABS stock?